XML 145 R17.htm IDEA: XBRL DOCUMENT

BORROWINGS

12 Months Ended

Dec. 31, 2025

NOTE 9 — BORROWINGS

Federal Funds Purchased, FHLB Advances, and Secured and Other Borrowings

Federal funds purchased and FHLBNY advances consisted of the following (in thousands):


									Interest Expense
		At			At				Year ended
		December 31,			December 31,				December 31,
		2025			2024				2025			2024			2023
Federal funds purchased and securities sold under agreements to repurchase		$	—		$	210,000			$	4,009		$	769		$	5,651
Federal Home Loan Bank of New York advances		$	—		$	240,000			$	7,310		$	11,659		$	17,321

Secured and other borrowings:
Secured borrowings		$	10,975		$	7,441				N.M			N.M			N.M
Federal Reserve Bank term loan		$	—		$	—			$	—		$	4,096		$	—

N.M. – not meaningful

Federal funds purchased are generally overnight transactions and had a weighted average interest rate of 4.48% at December 31, 2024. The FHLBNY advances are short-term transactions and had a fixed weighted average interest rate of 4.56% at December 31, 2024. There were no securities sold under agreements to repurchase outstanding as December 31, 2025 and 2024.

The Federal Reserve established the Bank Term Funding Program (“BTFP”) on March 12, 2023, as a funding source for eligible depository institutions. Advances can no longer be requested under the program. The BTFP was created to provide short-term liquidity (up to one-year) against the par value of certain high-quality collateral, such as U.S. Treasury securities. At December 31, 2025 and 2024, the Company had no outstanding FRB term loans under the BTFP.

At December 31, 2025, the Company had cash on deposit with the Federal Reserve Bank of New York and available secured wholesale funding borrowing capacity of $3.3 billion.

Trust Preferred Securities Payable

On December 7, 2005, the Company established MetBank Capital Trust I, a Delaware statutory trust (“Trust I”). The Company received all of the common stock of Trust I in exchange for contributed capital of $310,000. Trust I issued $10.0 million of preferred capital securities to investors in a private transaction and invested the proceeds, combined with the proceeds from the sale of Trust I’s common capital securities, in the Company through the purchase of $10.3 million aggregate principal amount of Floating Rate Junior Subordinated Debentures (the “Debentures”) issued by the Company. The Debentures, the sole assets of Trust I, mature on December 9, 2035 and are callable at any time. At December 31, 2025 and 2024 the Debentures bore interest at a floating rate of three-month SOFR plus 1.85%. The interest rates were 6.02% and 6.77% as of December 31, 2025 and 2024, respectively.

On July 14, 2006, the Company established MetBank Capital Trust II, a Delaware statutory trust (“Trust II”). The Company received all of the common stock of Trust II in exchange for contributed capital of $310,000. Trust II issued $10.0 million of preferred capital securities to investors in a private transaction and invested the proceeds, combined with the proceeds from the sale of Trust II’s common capital securities, in the Company through the purchase of $10.3 million aggregate principal amount of Floating Rate Junior Subordinated Debentures (the “Debentures II”) issued by the Company.

The Debentures II, the sole assets of Trust II, mature on October 7, 2036 and are callable at any time. At December 31, 2025 and 2024, the Debentures bore interest at a floating rate of three-month SOFR plus 2.00%. The interest rates were 6.17% and 6.92% as of December 31, 2025 and 2024, respectively.

The Company is not considered the primary beneficiary of these trusts; therefore, the trusts are not consolidated in the Company’s financial statements. Interest on the subordinated debentures may be deferred by the Company at any time or from time to time for a period not exceeding twenty consecutive quarterly payments (five years), provided there is no event of default. At the end of the deferral period, the Company must pay accrued interest, at which point it may elect a new deferral period provided that no deferral may extend beyond maturity.

The investments in the common stock of Trust I and Trust II are included in other assets on the consolidated statements of financial condition. The subordinated debentures may be included in Tier 1 capital (with certain applicable limitations) under current regulatory guidelines and interpretations.